MPE at ASH 2024: key research and expert insights on myelomaAL amyloidosis, CAR-T, Conferences, MPE, MyelomaDecember 16, 2024
Myeloma and AL amyloidosis ASH 2024 previewAccess, AL amyloidosis, CAR-T, MPE, MyelomaNovember 29, 2024
MPE webinar on ASH 2024 myeloma and AL amyloidosis highlightsAL amyloidosis, latest, MPE, Myeloma, NewsNovember 29, 2024
MPE provided feedback on the HTA Implementing Regulation on joint scientific consultations on medical devices and in vitro diagnostic medical devices at Union levellatest, MPE, NewsNovember 27, 2024
EMA CHMP gives positive opinion on isatuximab combination for newly diagnosed myeloma patientsAccess, latest, Myeloma, NewsNovember 20, 2024
MPE comments on the European Medicines Agency’s policy on the handling of competing interests of scientific committees’ members and expertsMPE, NewsNovember 14, 2024
MPE comments on the Implementing Regulation on joint scientific consultations on medicinal products for human use at Union levelAccess, latest, NewsOctober 29, 2024
A second bispecific antibody is approved as a fourth-line treatment for myeloma in England and WalesAccess, latest, Myeloma, NewsJuly 17, 2024
